한글목차

세계 재조합 인간 폴리트로핀 시장의 미래는 유망하며, 여성용 시장과 남성용 시장에서 기회가 있습니다. 세계 재조합 인간 폴리트로핀 시장은 2025년부터 2031년까지 CAGR 5.4%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 불임의 유병률 증가, 보조생식술 기술의 채택 증가, 바이오시밀러 치료의 가용성 확대 등입니다.

• Lucintel의 예측에 따르면, 유형별로는 150IU가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 여성용이 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

재조합 인간 폴리트로핀 시장의 새로운 동향

재조합 인간 폴리트로핀 산업은 역동적이며, 기술의 변화, 의료 행위의 진화, 환자들의 요구에 의해 주도되고 있습니다. 많은 주요 트렌드가 현재와 미래를 형성하고 있습니다.

• 바이오시밀러 수요 확대 : 오리지널 재조합 폴리트로핀의 특허가 만료됨에 따라 바이오시밀러 제제가 시장에 진입하고 있습니다. 바이오시밀러는 유사한 효능과 안전성 프로파일을 가지고 있으면서도 잠재적으로 더 저렴한 가격으로 환자들에게 더 친숙하고 저렴한 치료법을 제공할 수 있습니다. 바이오시밀러에 대한 우호적인 시각과 규제 당국의 승인 증가로 인해 바이오시밀러의 도입이 더욱 가속화되고, 시장에서의 가격 경쟁이 더욱 가속화될 것으로 보입니다.
• 개별 투여 요법 개발 : 연령, 난소예비력 마커, 자극에 대한 과거 반응 등 환자별 요인에 따라 맞춤화된 폴리트로핀 치료 프로토콜과 용량을 적용하는 움직임이 활발해지고 있습니다. 개별화 치료의 목적은 치료 결과를 개선하고 난소과자극증후군의 위험을 줄이는 것입니다. 예측 바이오마커와 개인별 맞춤 투여를 위한 알고리즘 연구가 본격화되고 있습니다.
• 보다 편리한 투여 장치 개발 : 제약사들은 미세한 바늘이 달린 프리필드 펜, 자동 주사 시스템 등 재조합 폴리트로핀의 편리한 투여 장치 개발에 힘쓰고 있습니다. 이 장치는 환자의 편의성을 높이고, 주사에 대한 두려움을 최소화하며, 치료 요법의 순응도를 높일 수 있도록 설계되었습니다. 자가 투약이 용이하다는 것은 전반적인 환자 경험의 향상으로 이어집니다.
• 지속형 폴리트로핀에 대한 관심 증가 : 지속형 재조합 폴리트로핀의 개발 및 출시가 인기를 끌고 있습니다. 이러한 제제는 매일 투여하는 제제보다 투여 횟수가 적어 환자의 순응도를 높이고 치료 부담을 줄일 수 있습니다. 임상시험을 통해 다양한 환자군에서 장시간 지속형 제제의 유효성과 안전성을 평가하고 있습니다.
• 전통적인 체외수정 이외의 용도 증가 : 체외수정 및 기타 보조생식기술에 주로 사용되지만, 자궁 내 인공수정을 위한 배란유도 및 일부 호르몬 불균형 치료 등 생식의료의 더 많은 분야에서 유전자 변형 폴리트로핀의 사용 가능성을 조사하고 있습니다. 이러한 용도 확대가 모색되면 유전자 변형 폴리트로핀의 시장 침투율이 높아질 수 있습니다.

이러한 향후 트렌드는 바이오시밀러를 통한 치료 접근성 향상, 개인별 맞춤 투여를 통한 치료 효율 극대화, 새로운 전달 장치 및 서방형 제제를 통한 환자 편의성 향상, 새로운 치료 용도 추구로 재조합 인간 폴리트로핀 시장을 변화시킬 것입니다. 이러한 추세는 환자 친화적이고 비용 효율성이 높은 향후 시장을 전망하고 있습니다.

재조합 인간 폴리트로핀 시장의 최근 동향

재조합 인간 폴리트로핀 시장은 치료 효과, 안전성, 환자 편의성 향상을 위한 발전으로 계속 성장하고 있습니다. 이러한 개발은 제품 라이프사이클의 다양한 분야에 걸쳐 이루어지고 있습니다.

• 새로운 바이오시밀러 제제 출시 : 초기 재조합 폴리트로핀 제제의 특허가 만료됨에 따라 다양한 시장에서 새로운 바이오시밀러 제제가 출시되고 있습니다. 이들 바이오시밀러 제제는 오리지널 제제와 유사한 품질, 유효성, 안전성을 입증하기 위해 광범위한 임상시험이 진행되어 환자들에게 저렴한 치료 옵션을 제공하고 시장에서의 경쟁을 강화하고 있습니다.
• 제조 및 정제 공정 개선 : 지속적인 연구개발 활동은 재조합 폴리트로핀의 제조 및 정제 공정의 합리화를 위한 것입니다. 이러한 개선은 제품의 품질을 향상시키고, 제조 비용을 낮추며, 증가하는 세계 수요를 충족시키기 위해 안정적인 공급을 목표로 하고 있습니다. 공정이 개선되면 더 순도가 높고 불순물이 적은 제품을 얻을 수 있습니다.
• 주사기 개발 개선 : 제약회사들은 재조합 폴리트로핀의 약물전달 기술을 지속적으로 발전시키고 있습니다. 이러한 개발에는 인체공학적으로 개선된 보다 편리한 프리필드 펜, 찌르는 듯한 통증을 줄이기 위한 미세한 주사바늘, 환자의 순응도를 높이고 자가투약으로 인한 약물 오남용을 줄이기 위한 정확한 투약 시스템 등이 있습니다.
• 약리유전체학 및 맞춤의료 : 약리유전체학을 활용하여 개별 환자의 재조합 폴리트로핀에 대한 반응을 예측할 수 있는 가능성을 연구하고 있습니다. 난소 자극에 대한 반응의 유전자 마커가 확인되면, 임상의는 치료 요법과 용량을 조정하여 성공률을 높이고 원치 않는 영향을 줄일 수 있을 것입니다.
• 새로운 치료 요법 임상시험 : 현재 임상시험에서는 시작 용량, 자극 기간, 다른 배란유도제와의 병용 등을 변경하는 등 재조합 폴리트로핀을 이용한 새로운 치료 요법을 평가하고 있습니다. 이러한 임상시험은 기존 프로토콜을 최적화하고, 다른 환자 하위 그룹에 대한 보다 성공적인 접근법을 결정하고, 궁극적으로 보조생식술의 전반적인 성공률을 향상시키기 위한 것입니다.

새로운 바이오시밀러 출시, 제조 및 전달 혁신, 맞춤형 의료에 대한 관심, 지속적인 임상 연구 등 재조합 인간 폴리트로핀 시장의 새로운 트렌드는 모두 치료의 접근성을 높이고, 제품의 품질과 환자 편의성을 높이며, 임상 결과를 개선함으로써 시장에 영향을 미치고 있습니다. 시장에 영향을 미치고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 재조합 인간 폴리트로핀 시장 : 종류별

• 개요
• 매력 분석 : 종류별
• 75IU : 동향과 예측(2019-2031년)
• 150IU : 동향과 예측(2019-2031년)
• 300IU : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제5장 세계의 재조합 인간 폴리트로핀 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 여성용 : 동향과 예측(2019-2031년)
• 남성용 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 재조합 인간 폴리트로핀 시장 : 지역별

제7장 북미의 재조합 인간 폴리트로핀 시장

• 개요
• 북미의 재조합 인간 폴리트로핀 시장 : 종류별
• 북미의 재조합 인간 폴리트로핀 시장 : 용도별
• 미국의 재조합 인간 폴리트로핀 시장
• 멕시코의 재조합 인간 폴리트로핀 시장
• 캐나다의 재조합 인간 폴리트로핀 시장

제8장 유럽의 재조합 인간 폴리트로핀 시장

• 개요
• 유럽의 재조합 인간 폴리트로핀 시장 : 종류별
• 유럽의 재조합 인간 폴리트로핀 시장 : 용도별
• 독일의 재조합 인간 폴리트로핀 시장
• 프랑스의 재조합 인간 폴리트로핀 시장
• 스페인의 재조합 인간 폴리트로핀 시장
• 이탈리아의 재조합 인간 폴리트로핀 시장
• 영국의 재조합 인간 폴리트로핀 시장

제9장 아시아태평양의 재조합 인간 폴리트로핀 시장

• 개요
• 아시아태평양의 재조합 인간 폴리트로핀 시장 : 종류별
• 아시아태평양의 재조합 인간 폴리트로핀 시장 : 용도별
• 일본의 재조합 인간 폴리트로핀 시장
• 인도의 재조합 인간 폴리트로핀 시장
• 중국의 재조합 인간 폴리트로핀 시장
• 한국의 재조합 인간 폴리트로핀 시장
• 인도네시아의 재조합 인간 폴리트로핀 시장

제10장 기타 지역(ROW)의 재조합 인간 폴리트로핀 시장

• 개요
• 기타 지역(ROW)의 재조합 인간 폴리트로핀 시장 : 종류별
• 기타 지역(ROW)의 재조합 인간 폴리트로핀 시장 : 용도별
• 중동의 재조합 인간 폴리트로핀 시장
• 남미의 재조합 인간 폴리트로핀 시장
• 아프리카의 재조합 인간 폴리트로핀 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 협상력
  • 공급업체의 협상력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 종류별
  • 성장 기회 : 용도별
• 세계의 재조합 인간 폴리트로핀 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증·라이선싱
  • 기업 인수합병(M&A) , 계약, 제휴, 합작투자

제13장 밸류체인 위 주요 기업 개요

• 경쟁 분석
• Merck
• Organon
• Gedeon Richter
• Ferring
• Changchun High-Tech
• Theramex
• Qilu Pharmaceutical

제14장 부록

• 그림목차
• 표목차
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global recombinant human follitropin market looks promising with opportunities in the women and men markets. The global recombinant human follitropin market is expected to grow with a CAGR of 5.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of infertility, the rising adoption of assisted reproductive technologies, and the growing availability of biosimilar treatments.

• Lucintel forecasts that, within the type category, 150IU is expected to witness the highest growth over the forecast period.
• Within the application category, women are expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Recombinant Human Follitropin Market

The recombinant human follitropin industry is dynamic and is driven by changes in technology, evolving medical practices, and patient requirements. A number of key trends are shaping its present and future.

• Growing Demand for Biosimilars: As patents on original recombinant follitropin products expire, biosimilar versions are entering the market. The biosimilars have similar efficacy and safety profiles at potentially lower prices, making treatment more accessible and affordable to patients. The increasing favor and regulatory approvals for biosimilars are likely to further accelerate their adoption, fostering more price competition in the marketplace.
• Developments in Individualized Dosing Regimens: Increasingly, there is a move towards customizing follitropin treatment protocols and dosing according to patient-specific factors, including age, markers for ovarian reserve, and prior response to stimulation. The goal of individualized therapy is to enhance therapeutic outcomes and reduce the risk of ovarian hyperstimulation syndrome. Investigation into predictive biomarkers and algorithmic studies for individualized dosing is in full swing.
• Creation of More Convenient Delivery Devices: Pharmaceutical firms are working on creating convenient delivery devices for recombinant follitropin, including prefilled pens with thin needles and automatic injection systems. These devices are designed to enhance patient convenience, minimize injection fear, and increase compliance with treatment regimens. Ease of self-administration leads to an improved overall patient experience.
• Increasing Interest in Long-Acting Follitropin Preparations: The creation and launch of long-acting recombinant follitropin preparations are increasing in popularity. These preparations involve less frequent administration than daily preparations, which could enhance patient compliance and decrease the treatment burden. Clinical trials are assessing the efficacy and safety of longer-acting formulations across different patient populations.
• Increasing Uses Beyond Conventional IVF: Though predominantly employed in in vitro fertilization and other assisted reproductive technologies, the study is investigating the possible uses of recombinant follitropin in more fields of reproductive health, including ovulation induction for intrauterine insemination and treatment of some hormonal imbalances. The exploration of these expanded uses may increase the market penetration of recombinant follitropin.

These upcoming trends are combined to transform the recombinant human follitropin market by enhancing the accessibility of treatments through biosimilars, maximizing treatment efficiency through individualized dosing, improving patient convenience with new delivery devices and extended-release formulations, and seeking novel therapeutic uses. These trends look towards a patient-friendly and more cost-efficient future market.

Recent Developments in the Recombinant Human Follitropin Market

The recombinant human follitropin market continues to grow with advances aimed at enhancing treatment effectiveness, safety, and patient comfort. These developments cover different areas of the product life cycle.

• Launch of New Biosimilar Formulations: Patent expirations for a number of initial recombinant follitropin products have resulted in the launch of new biosimilar formulations in various markets. These biosimilars are tested extensively to prove similar quality, efficacy, and safety to the originator products, providing cheaper treatment alternatives for patients and enhancing competition in the market.
• Improvements in Manufacturing and Purification Processes: Continued research and development activities are directed towards streamlining the manufacturing and purification processes of recombinant follitropin. Such improvements are intended to improve product quality, lower the costs of production, and provide a consistent supply to fulfill the increasing global demand. Better processes can also result in products that are higher in purity and possibly lower in impurities.
• Improved Injection Device Development: Pharmaceutical manufacturers are constantly developing advances in drug delivery technology in the form of recombinant follitropin. Some of these developments include more convenient prefilled pens that have improved ergonomics, thinner needles to reduce stinging, and precise dosing systems to enhance patient compliance and decrease drug errors with self-administration.
• Pharmacogenomics and Personalized Medicine: Research is investigating the possibility of using pharmacogenomics to anticipate response to recombinant follitropin in individual patients. The identification of genetic markers of response to ovarian stimulation could allow clinicians to tailor treatment regimens, doses, and even enhance success rates and reduce unwanted effects.
• Clinical Trials for New Treatment Regimens: Current clinical trials are evaluating new treatment regimens with recombinant follitropin, such as varying the dose of initiation, duration of stimulation, and combination with other fertility drugs. These trials seek to optimize existing protocols and determine more successful approaches for other patient subgroups, ultimately leading to overall enhanced success with assisted reproductive technology.

These new trends in the recombinant human follitropin market, such as the launch of new biosimilars, innovation in manufacturing and delivery, emphasis on personalized medicine, and continued clinical studies, are all influencing the market by making treatment more accessible, enhancing product quality and patient ease, and reaching for improved clinical outcomes.

Strategic Growth Opportunities in the Recombinant Human Follitropin Market

The recombinant human follitropin market presents several strategic growth opportunities across its primary application in assisted reproductive technologies and related infertility treatments.

• Increasing Access in Underserved Geographies: A key area of opportunity for growth is increasing access to recombinant follitropin in emerging markets and underserved territories with limited access to cutting-edge fertility treatment due to cost and infrastructure. Building partnerships with in-country healthcare providers and instituting tiered pricing practices can help gain traction in these markets and serve the unmet need of a large population of patients.
• Growing Adoption in Intrauterine Insemination (IUI): Though predominantly applied with IVF, recombinant follitropin can also be used to increase the success of IUI by stimulating the growth of several mature follicles. Strategic initiatives to make fertility experts aware of recombinant follitropin's advantages when included in IUI treatment protocols and to increase its availability for this purpose can fuel market growth in this segment.
• Personalizing Controlled Ovarian Stimulation Regimens for Individual Patient Profiles: Customization of COS regimens with recombinant follitropin on the basis of patient-specific characteristics, including age, BMI, AMH level, and past ART history, presents a major potential to maximize success rates and minimize side effects. Establishing and marketing evidence-based individualized stimulation protocols can further maximize the value proposition of recombinant follitropin.
• Taking Advantage of Fertility Tourism Growth: The growing phenomenon of fertility tourism, where patients go abroad for lower-cost or specialty fertility care, offers an opportunity for growth for clinics and vendors in destination countries. Having high-quality recombinant follitropin and standardized treatment protocols available in these facilities can bring more overseas patients.
• Investigating Co-marketing and Combination Therapies: Cooperating with firms providing complementary fertility treatments or formulating combination therapies that include recombinant follitropin with other gonadotropins or adjunctive therapies can open new avenues for growth. Establishing the synergistic value of such combinations through clinical studies can improve therapy effectiveness and expand the recombinant follitropin market.

These strategic growth prospects, including geographical expansion, wider usage in ART, individualized treatment strategies, utilization of fertility tourism, and examining combination therapies, have the capability to take the recombinant human follitropin market by storm by targeting more patients and maximizing treatment outcomes.

Recombinant Human Follitropin Market Driver and Challenges

The recombinant human follitropin market is influenced by a myriad of drivers and challenges, including technological innovation, economic considerations, and the regulatory environment. It is essential for stakeholders in this industry to understand these influences.

The factors responsible for driving the recombinant human follitropin market include:

1. Rising Incidence of Infertility: The global prevalence of infertility is increasing due to various factors, including lifestyle changes, environmental pollution, and delaying childbearing. This growing need for effective fertility treatments, where recombinant follitropin plays a crucial role in ovarian stimulation, is a primary driver of market growth.

2. Technology Advances in Assisted Reproductive Technologies (ART): Unceasing innovations in ART processes, including IVF and ICSI, have made them very successful and in greater demand. Recombinant follitropin is the building block technology behind these procedures, making it increasingly in demand in tandem with the growth of the ART market.

3. Expanding Awareness and Acceptance of Fertility Treatment: As society becomes more aware of infertility as a health issue and less stigmatized about seeking treatment, more people and couples are turning to fertility interventions. That expanded acceptance means a greater pool of patients for recombinant follitropin.

4. Recombinant Superiority Over Urinary-Derived Products: Recombinant human follitropin has more purity, batch-to-batch consistency, and a lower viral contamination risk than traditional urinary-derived FSH. Its benefits have resulted in its popularity as the product of choice for ovarian stimulation, driving market growth.

5. Increasing Healthcare Spending in Developing Economies: As developing economies witness growth in healthcare spending and infrastructure, access to sophisticated fertility treatments, such as recombinant follitropin, is becoming better. This greater affordability and availability in erstwhile underserved markets are major drivers of market growth.

Challenges in the recombinant human follitropin market are:

1. High Cost of Treatment: The total cost of ART cycles, including the expense of recombinant follitropin medications, can be prohibitive to many couples. This is a high cost that can pose a financial hurdle to receiving the treatment, especially in areas with meager insurance coverage or public funds for fertility treatment.

2. Strict Regulatory Approvals: The creation and marketing of recombinant biologics such as follitropin are subjected to rigorous regulatory review in a process that protects safety and efficacy. This challenging and sometimes lengthy set of approval processes can be challenging for manufacturers, potentially slowing the entry into the market and raising costs of development.

3. Risk of Ovarian Hyperstimulation Syndrome: Although recombinant follitropin is safe in general, the possibility of ovarian hyperstimulation syndrome, a potentially severe complication of ovarian stimulation, poses a continued concern. Clinicians have to monitor patients carefully and modify treatment protocols to avoid this risk, which can impact prescribing behaviors.

In summary, the recombinant human follitropin market is fueled mainly by the rising incidence of infertility, innovative progress in ART, rising awareness about treatment, and the benefits of recombinant technology. But challenges such as the issue of high treatment cost, strict regulatory demands, and the risk of OHSS must be countered to promote easier access and safer use of these critical drugs.

List of Recombinant Human Follitropin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, recombinant human follitropin companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the recombinant human follitropin companies profiled in this report include:

• Merck
• Organon
• Gedeon Richter
• Ferring
• Changchun High-Tech
• Theramex
• Qilu Pharmaceutical

Recombinant Human Follitropin Market by Segment

The study includes a forecast for the global recombinant human follitropin market by type, application, and region.

Recombinant Human Follitropin Market by Type [Value from 2019 to 2031]:

• 75IU
• 150IU
• 300IU
• Others

Recombinant Human Follitropin Market by Application [Value from 2019 to 2031]:

• Women
• Men

Recombinant Human Follitropin Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Recombinant Human Follitropin Market

Current trends in the recombinant human follitropin market follow wider trends for infertility therapy across the world. Recombinant human follitropin, which is a highly purified follicle-stimulating hormone, has benefits regarding consistency and lower immunogenicity over the previously used older, urinary-derived compounds. The rise in infertility incidence, together with advances in assisted reproductive technologies, is driving market growth in major geographic regions. Regulatory environments, the advent of biosimilars, and increased interest in personalized medicine are all helping drive the changing dynamics of this market. This primer sets a context for discussing particular developments in the United States, China, Germany, India, and Japan.

• United States: The US market for recombinant human follitropin is marked by high rates of adoption of assisted reproductive technologies and a strong focus on advanced treatments. Recent events include ongoing efforts to maximize stimulation protocols toward individualized patient outcomes. In addition, the market is seeing growing debates regarding the cost-effectiveness of various follitropin products and the resultant effects of future biosimilar introductions. Patient advocacy groups are also involved in influencing treatment guidelines and access to care.
• China: The recombinant human follitropin market in China is growing at a very fast rate, with increased awareness of infertility and increased availability of assisted reproductive technologies. The latest events in the market involve the approval and launch of locally manufactured recombinant follitropin to make the product more affordable and available. Developing family planning policies of the government are also adding to the increased potential pool of patients. There is an increasing focus on quality and safety standards of locally produced biologics.
• Germany: Germany's mature recombinant human follitropin market has a high concentration of established pharmaceutical firms and growing biosimilar product adoption. Recent trends have been price competition arising from the presence of biosimilars, impacting the cost of treatment. Emphasis is on providing high-quality patient care and improving treatment regimens within the context of an established health system. Improved formulations and delivery systems are still being researched.
• India: The Indian market for recombinant human follitropin is growing with an increasing number of infertility clinics and awareness of treatments available. New developments include the increased availability of both imported and locally produced recombinant follitropin. Plans are being made to make these treatments available at a lower cost and to a wider portion of the population. Regulatory routes for biosimilars are also being shaped, potentially resulting in more affordable alternatives in the future.
• Japan: The Japanese recombinant human follitropin market has experienced a steady rise in use, corresponding to increasing demand for infertility treatment. Recent trends include user-friendly injectors and patient convenience and comfort. While the willingness to adopt new therapy is conservative, the expanding social acceptability of assisted reproductive technologies is driving market expansion. Market access remains influenced by regulatory factors particular to the Japanese healthcare system.

Features of the Global Recombinant Human Follitropin Market

• Market Size Estimates: Recombinant human follitropin market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Recombinant human follitropin market size by type, application, and region in terms of value ($B).
• Regional Analysis: Recombinant human follitropin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the recombinant human follitropin market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the recombinant human follitropin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the recombinant human follitropin market by type (75IU, 150IU, 300IU, and others), application (women and men), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Recombinant Human Follitropin Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 75IU: Trends and Forecast (2019-2031)
• 4.4 150IU: Trends and Forecast (2019-2031)
• 4.5 300IU: Trends and Forecast (2019-2031)
• 4.6 Others: Trends and Forecast (2019-2031)

5. Global Recombinant Human Follitropin Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Women: Trends and Forecast (2019-2031)
• 5.4 Men: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Recombinant Human Follitropin Market by Region

7. North American Recombinant Human Follitropin Market

• 7.1 Overview
• 7.2 North American Recombinant Human Follitropin Market by Type
• 7.3 North American Recombinant Human Follitropin Market by Application
• 7.4 United States Recombinant Human Follitropin Market
• 7.5 Mexican Recombinant Human Follitropin Market
• 7.6 Canadian Recombinant Human Follitropin Market

8. European Recombinant Human Follitropin Market

• 8.1 Overview
• 8.2 European Recombinant Human Follitropin Market by Type
• 8.3 European Recombinant Human Follitropin Market by Application
• 8.4 German Recombinant Human Follitropin Market
• 8.5 French Recombinant Human Follitropin Market
• 8.6 Spanish Recombinant Human Follitropin Market
• 8.7 Italian Recombinant Human Follitropin Market
• 8.8 United Kingdom Recombinant Human Follitropin Market

9. APAC Recombinant Human Follitropin Market

• 9.1 Overview
• 9.2 APAC Recombinant Human Follitropin Market by Type
• 9.3 APAC Recombinant Human Follitropin Market by Application
• 9.4 Japanese Recombinant Human Follitropin Market
• 9.5 Indian Recombinant Human Follitropin Market
• 9.6 Chinese Recombinant Human Follitropin Market
• 9.7 South Korean Recombinant Human Follitropin Market
• 9.8 Indonesian Recombinant Human Follitropin Market

10. ROW Recombinant Human Follitropin Market

• 10.1 Overview
• 10.2 ROW Recombinant Human Follitropin Market by Type
• 10.3 ROW Recombinant Human Follitropin Market by Application
• 10.4 Middle Eastern Recombinant Human Follitropin Market
• 10.5 South American Recombinant Human Follitropin Market
• 10.6 African Recombinant Human Follitropin Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Recombinant Human Follitropin Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Merck
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Organon
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Gedeon Richter
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Ferring
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Changchun High-Tech
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Theramex
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Qilu Pharmaceutical
  • Company Overview
  • Recombinant Human Follitropin Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us